Companies · Other
LAUREL · Other
Diligence memoA one-page analyst read on Laurel Biocomposite Llc — recommendation, valuation, rhythm, risks.→Laurel Biocomposite Llc looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Laurel Biocomposite Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Laurel Biocomposite Llc is one of 25015 Other companies tracked from LAUREL. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Benchmarked against 25015 companies in Other. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 88% of sector peers (real $). Modeled value above 14% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #64 of 64.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Petaquilla Minerals Ltd | Series B | $40.0M | $664.6M | 1.75× |
| Wageworks, Inc. | Series B | $60.0M | $664.6M | 1.75× |
| MetWest-SIMA Real Estate Fund I LLC | Series B | $39.5M | $655.5M | 1.73× |
| Xora Inc | Series B | $37.5M | $623.7M | 1.65× |
| Cbs Personnel Holdings Inc | Series B | $35.0M | $581.5M | 1.53× |
| Rembrandt Venture Partners Fund Two Lp | Series B | $35.0M | $581.5M | 1.53× |
| FTV-CP Investment Inc. | Series B | $35.0M | $581.5M | 1.53× |
| Argonaut Gold Inc. | Series B | $34.2M | $568.2M | 1.50× |
| WP Evenflo Group Holdings, Inc. | Series B | $33.3M | $552.4M | 1.46× |
| Accruent Holdings, Inc. | Series B | $32.0M | $531.7M | 1.40× |
| Allied Gold Ltd | Series B | $58.8M | $523.9M | 1.38× |
| Volcan Holdings, Inc. | Series B | $32.8M | $523.4M | 1.38× |
| Laurel Biocomposite Llc this company | Series B | $25.9M | $2.4M | 0.01× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $106K | 2009-10-19 | $589K | $2.4M | 90% |
| Pre-Seed | $324K | — | $1.8M | $540K | 90% |
| Seed | $2.0M | — | $10.0M | $4.0M | 90% |
| Series B | $21.0M | — | $116.7M | $79.3M | 90% |
| Seed | $2.5M | — | $12.5M | $5.0M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Gary Metzger | — | 1 other | — |
| Seth Harder | — | 1 other | — |
| A.D. Felber | — | — | 2009-10 |
| Boyd A. Ebberson | — | — | 2009-10 |
| Boyd Ebberson | — | — | — |
| Cecil O'Brate | — | — | — |
| Daniel Grams | — | — | — |
| Daniel Scott Grams | — | — | 2009-10 |
| Dave Felbar | — | — | — |
| Dave Felber | — | — | — |
| Gary A. Metzger | — | — | 2009-10 |
| Jeff Torluemke | — | — | 2009-10 |
| Keith Knudsen | — | — | — |
| Keith Scott Knudsen | — | — | 2009-10 |
| Louis A. Luedtke | — | — | 2009-10 |
| Margery Lauer | — | — | 2009-10 |
| Mike Dunklau | — | — | — |
| Richard, Jr. E. Adkins | — | — | 2009-10 |
| Ron E. Hageman | — | — | 2009-10 |
| Ron Hageman | — | — | — |
| Terry Wilkerson | — | — | — |
| Theodore A. Kesten | — | — | 2009-10 |
| Theodore Kesten | — | — | — |
| Tim Bearnes | — | — | 2009-10 |
Laurel Biocomposite Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| PetPlate, Inc. | Other | Series B | $31.5M | $2.3M | same sector · same stage |
| Raydiant, Inc. | Other | Series B | $20.5M | $2.5M | same sector · same stage |
| Ecoark Holdings, Inc. | Other | Series C | $109.6M | $1.0B | network1 shared operator · same sector |
| Reklaim Inc | Other | Series A | $26.1M | $2.5M | same sector |
| Interline Brands, Inc./De | Other | Series A | $17.6M | $2.4M | same sector |
| Ultra Green Packaging, Inc. | Other | Series A | $17.3M | $2.4M | same sector |
| Grand Little Pink House LLC | Other | Series B | $350K | $2.6M | same sector · same stage |
| MICRON RESOURCES Corp | Other | Series A | $14.3M | $2.6M | same sector |
See where Laurel Biocomposite Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Laurel Biocomposite Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.